Sydney, Australia 4 July 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Kathleen Miller, a US based experienced business development executive, to Clarity’s team.
Dr Miller has over 25 years of experience in the pharmaceutical, medical imaging, and medical device industries, most recently as Director of Business Development at Mallinckrodt Pharmaceuticals. She brings to Clarity a unique combination of skills and experience of business development and transactions in relevant pharmaceutical areas.
Dr Miller began her pharmaceutical career in R&D at Mallinckrodt, successfully leading the development of a radiopharmaceutical orphan drug that is still in commercial use today. She then spent four years marketing interventional and radio-therapeutic devices prior to moving into business development. She has 15 years’ experience at Mallinckrodt in business development where she was instrumental in completing the transformational divestitures of two medical imaging businesses and in executing licensing, technology transfer, commercialisation, and product development transactions. She also has experience in alliance management and integration. In addition, Kathy spent two years leading an interventional R&D project on embolic fluids at a start-up medical device company in St. Louis.
Dr Miller commented “I am very excited to be joining Clarity at this important stage when the Company is actively extending and progressing its pipeline in a number of clinical trials and gains validation and worldwide recognition of its proprietary technology. I hope that my expertise will help to commercialise these treatments which address the unmet medical needs of children and adults with cancer”.
Clarity’s Executive Chairman Dr Alan Taylor said “Dr Miller is an experienced professional with many years of completing successful transactions and we welcome her at a time when the company is receiving lots of interest in our pipeline from a number of strategic companies. Her expertise in business development combined with deep knowledge of radiotherapeutics will be beneficial for Clarity as the Company enters a more mature stage of its development and commences a number of clinical trials. We believe that Dr Miller’s appointment will prove invaluable for extending Clarity’s partnerships, capitalising on our existing networks and progressing current negotiations with strategic parties.”
Dr Miller received a Bachelor of Science degree in chemistry at the University of Illinois in Champaign-Urbana, a Ph.D. in Inorganic Chemistry at the University of California in Los Angeles, and an Executive MBA at Washington University in St. Louis.
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
